This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Richert, N. D Articles by Frank, J. A Search for Related Content PubMed PubMed Citation Articles by Richert, N. D Articles by Frank, J. A Social Bookmarking                         What's this?

MRI and clinical activity in MS patients after terminating treatment with interferon beta-l b

Laboratory of Diagnostic Radiology Research, Clinical Center, NIH-Bethesda, Maryland, MD 20892, USA, Department of Diagnostic Imaging and Radiology, Children's National Medical Center, Washington DC, USA

Mary Christina Zierak

Laboratory of Diagnostic Radiology Research, Clinical Center, NIH-Bethesda, Maryland, MD 20892, USA

Craig N Bash

Laboratory of Diagnostic Radiology Research, Clinical Center, NIH-Bethesda, Maryland, MD 20892, USA, Department of Radiology an d Nuclear Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

Bobbi K Lewis

Laboratory of Diagnostic Radiology Research, Clinical Center, NIH-Bethesda, Maryland, MD 20892, USA

Henry F McFarland

Laboratory of Diagnostic Radiology Research, Clinical Center, NIH-Bethesda, Maryland, MD 20892, USA

Joseph A Frank

Laboratory of Diagnostic Radiology Research, Clinical Center, NIH-Bethesda, Maryland, MD 20892, USA

Monthly MRI activity and clinical disability were evaluated in two relapsing-remitting multiple sclerosis (RRMS) patient for 4 years during a cross-over treatment trial with IFNß-Ib, and for a mean of 21 months after terminating treatment with IFNß-Ib. Post-treatment MRI activity was compared to baseline activity in these patient. Although contrast enhancing lesions (CEL) and the bulk white matter lesion load (BWMLL) on T2-weighted images eventually returned to baseline values, there was a refractory period of 6-10 months after terminating treatment before baseline MRI activity was restored. Although the mechanism for a sustained effect of IFNß- Ib is unclear at this time, these result have important implications for enrollment of such patients into new treatment protocols that rely on contrast enhancing lesion frequency as an outcome measure.

Key Words: multiple scerosis • magnetic resonance imaging • interferon beta-Ib

Multiple Sclerosis, Vol. 6, No. 2, 86-90 (2000)
DOI: 10.1177/135245850000600206


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. R. Pachner, D. Cadavid, L. Wolansky, and J. Skurnick Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study Neurology, November 3, 2009; 73(18): 1485 - 1492. [Abstract] [Full Text] [PDF]

				S Minden, D Hoaglin, S Jureidini, L Hadden, D Frankel, Y Komatsuzaki, and J Outley Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study Multiple Sclerosis, June 1, 2008; 14(5): 640 - 655. [Abstract] [PDF]

				R. Farrell, R. Kapoor, S. Leary, P. Rudge, A. Thompson, D. Miller, and G. Giovannoni Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta Multiple Sclerosis, March 1, 2008; 14(2): 212 - 218. [Abstract] [PDF]

				A.R. Pachner Neutralizing anti-IFN{beta} antibodies: clarity and confusion Multiple Sclerosis, November 1, 2007; 13(9): 1081 - 1082. [PDF]

				A.T. Reder Neutralizing antibodies in multiple sclerosis: a complex impact on interferon responses, magnetic resonance imaging findings and clinical outcomes Multiple Sclerosis, May 1, 2007; 13(1_suppl): 53 - 62. [Abstract] [PDF]

				G. Giovannoni, C. H. Polman, J. Petkau, R. White, A. Thompson, D. H. Miller, F. Dahlke, and L. Kappos Neutralizing antibodies during treatment of secondary progressive MS with interferon {beta}-1b Neurology, October 14, 2003; 61(7): 1025 - 1025. [Full Text] [PDF]

				A. Langer-Gould, H. Garren, A. Slansky, P. J. Ruiz, and L. Steinman Late Pregnancy Suppresses Relapses in Experimental Autoimmune Encephalomyelitis: Evidence for a Suppressive Pregancy-Related Serum Factor J. Immunol., July 15, 2002; 169(2): 1084 - 1091. [Abstract] [Full Text] [PDF]